Molecular Bioengineering Laboratory, Division of Chemistry for Materials, 1577 Kurima-Machiya-cho, Tsu, Mie 514-8507, Japan.
Intelectual Property Office (IPO), Organization for the Promotion of Regional Innovation, 1577 Kurima-Machiya-cho, Tsu, Mie 514-8507, Japan.
Immunotherapy. 2019 Feb;11(2):119-127. doi: 10.2217/imt-2018-0130.
Attention to therapeutic monoclonal antibodies has been dramatically increasing year by year. Their highly specific targeting of antigens can provide very effective medical treatment, and the advent of molecular-targeting medicine is allowing development of a new generation of therapeutic agents. However, there is one critical obstacle to overcome. Most of the established therapeutic monoclonal antibodies have specificity for the primary structures of target antigens, although all proteins harbor original native intact structures for their own specific functions. Stereo-specific monoclonal antibodies recognizing conformational structures of target antigens may thus offer a markedly more versatile approach. Their application may change the very concepts underlying use of therapeutic antibodies.
近年来,人们对治疗性单克隆抗体的关注度显著增加。它们对抗原的高度特异性靶向可以提供非常有效的治疗,而分子靶向药物的出现也使得新一代治疗药物的开发成为可能。然而,有一个关键的障碍需要克服。大多数已建立的治疗性单克隆抗体针对靶抗原的一级结构具有特异性,尽管所有蛋白质都具有原始的完整结构以实现其特定功能。因此,识别靶抗原构象结构的立体特异性单克隆抗体可能提供一种更灵活的方法。它们的应用可能会改变治疗性抗体使用的基本概念。